Search results
Ipsen drug approved by FDA for early pancreatic cancer
BioPharma Dive via Yahoo Finance· 3 months agoDive Brief: The Food and Drug Administration has approved a new regimen for pancreatic cancer,...
Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen
Zacks via Yahoo Finance· 2 years agoIpsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in...
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
BioPharma Dive via Yahoo Finance· 4 weeks agoDive Brief: French pharmaceutical company Ipsen will work with privately held biotechnology company...
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
Benzinga via Yahoo Finance· 1 year agoIpsen (OTC: IPSEY) has agreed to acquire Albireo Pharma Inc (NASDAQ: ALBO) at $42.00 per share in...
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
Benzinga via Yahoo Finance· 11 months agoIpsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) announced topline data from the Phase 3 ELATIVE...
Is IPSEN (IPSEY) Outperforming Other Medical Stocks This Year?
Zacks via Yahoo Finance· 1 year agoFor those looking to find strong Medical stocks, it is prudent to search for companies in the group...
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Benzinga via Yahoo Finance· 2 years agoIpsen SA (OTC: IPSEY) has agreed to acquire Epizyme Inc (NASDAQ: EPZM) at $1.45 per share for...
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
Benzinga via Yahoo Finance· 2 years agoMerrimack Pharmaceuticals Inc's (NASDAQ: MACK) partner announced that Ipsen SA (OTC: IPSEY) reported...
AbbVie, Ipsen Terminate Partnerships With Exicure As Bankruptcy Concern Looms
Benzinga via Yahoo Finance· 1 year agoExicure Inc (NASDAQ: XCUR) announced the termination of its collaboration agreements with AbbVie Inc...
Why Merrimack Shares Are Surging Over 200% Today?
Benzinga via Yahoo Finance· 2 years agoIpsen SA (OTC: IPSEY) announced that the Phase 3 NAPOLI 3 trial of Onivyde plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its...